Testing AK152 in healthy people and Alzheimer's patients
Part of Brain & nervous system clinical trials.
This trial tests a new drug called AK152, first in healthy volunteers to check safety, then in people with mild Alzheimer's disease or mild cognitive impairment due to Alzheimer's. It aims to see if the drug is safe and well-tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: you must be 18 to 40 years old.
- For Alzheimer's participants: you must be 50 to 85 years old.
- You must have a body mass index (BMI) within a certain range (19–26 for healthy, 17–35 for Alzheimer's).
- If you have Alzheimer's, you need a study partner who can join you.
- You must not have had cancer in the last 5 years (except some minor skin cancers).
- You cannot have other major brain disorders or recent strokes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This trial tests a new medicine called AK139 in healthy people to see how safe it is and how the body processes it. It is for healthy adults aged 18 to 55.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This trial tests a new drug called AK0610 in healthy volunteers aged 18 to 50. It helps researchers understand how the drug works in the body and whether it is safe before moving to larger studies.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.